Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ) Bundle
Founded in 1996, Sichuan Kelun Pharmaceutical Co., Ltd. has grown into a Chengdu-based powerhouse whose mission to 'explore new cures with scientific and ethical excellence' drives heavy R&D investment-amounting to billions-and a comprehensive innovation system that supports both large- and small-volume injections, sterile powders, oral formulations and medical devices; with a market value exceeding 100 billion RMB and a top-three standing in China's pharmaceutical manufacturing sector, Kelun pairs a global vision to address oncology, bacterial infections and parenteral nutrition with concrete achievements including more than 3,000 patents and over 2,000 patent authorizations, a customer satisfaction rate of 92%, and decades-long social responsibility demonstrated by donations in the tens of millions of Yuan and nearly 30 million Yuan to the 2008 Wenchuan Earthquake-inviting readers to explore how its mission, vision and core values translate into measurable impact across healthcare, innovation and public welfare
Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ) - Intro
Overview Sichuan Kelun Pharmaceutical Co., Ltd., established in 1996 in Chengdu, Sichuan, is a leading integrated pharmaceutical manufacturer focused on R&D, production and commercialization of injectable and oral drug forms and medical devices. The company's strategic therapeutic priorities include oncology, bacterial infections and parenteral nutrition, serving domestic and international markets. With a market capitalization exceeding 100 billion RMB, Kelun ranks among the top three Chinese pharmaceutical manufacturers by market value.- Founded: 1996 (Chengdu, Sichuan)
- Primary products: large & small volume injections, sterile powder injections, tablets, capsules, medical devices
- Therapeutic focus: oncology, bacterial infections, parenteral nutrition
- Market value: >100 billion RMB
- Deliver safe, effective and affordable medicines that address critical clinical needs at scale.
- Advance patient outcomes through continuous innovation in injectable and parenteral therapies.
- Operate with integrity and social responsibility, prioritizing patient safety and public health.
- Become a globally recognized pharmaceutical leader in injectable therapeutics and oncology solutions.
- Drive sustainable growth through innovation, manufacturing excellence and international expansion.
- Build an R&D-driven enterprise that translates scientific breakthroughs into accessible therapies.
- Patient Centricity - patient safety and clinical benefit guide decisions.
- Innovation - sustained investment in R&D to develop first-in-class and best-in-class products.
- Quality & Compliance - rigorous quality systems for sterile production and regulatory adherence.
- Integrity & Responsibility - ethical business conduct and active social contribution.
- Collaboration - partnership across industry, academia and healthcare systems to scale impact.
| Metric | Figure / Description |
|---|---|
| Establishment | 1996 (Chengdu, Sichuan) |
| Market Capitalization | >100 billion RMB |
| R&D Investment | Multi-year cumulative investment in the billions of RMB |
| Patents | >3,000 patents filed; >2,000 patent authorizations |
| Core Therapeutic Areas | Oncology; Bacterial infections; Parenteral nutrition |
| Product Types | Large & small volume injections; Sterile powder injections; Tablets; Capsules; Medical devices |
| Social Contributions | Tens of millions of Yuan donated; ~30 million Yuan to 2008 Wenchuan Earthquake relief |
Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ) - Overview
Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ) frames its corporate purpose around a concise mission: 'explore new cures with scientific and ethical excellence.' That mission guides priorities across quality, innovation, customer focus, and ethics, and is embedded in operational targets, product development, and stakeholder engagement.- Quality & compliance: strict adherence to regulatory standards and GMP across manufacturing and quality-control processes to ensure safety and efficacy.
- Innovation & R&D: sustained commitment to drug discovery, formulation and delivery improvements to expand therapeutic options.
- Customer-centricity: orienting product development and service delivery around clinicians' and patients' needs; measured customer satisfaction of 92% (internal survey).
- Ethics & transparency: governance and reporting practices designed to build trust with investors, partners and regulators.
| Pillar | Operational focus | Representative metric / statement |
|---|---|---|
| Mission | Advance healthcare through scientific and ethical excellence | 'Explore new cures with scientific and ethical excellence' (corporate mission) |
| Quality | Product safety, regulatory compliance, manufacturing control | GMP-compliant production and formal quality management systems across sites |
| Innovation | R&D in formulations, delivery systems, and clinical development | Ongoing pipeline development and reinvestment in research capacity |
| Customer Focus | Meeting needs of healthcare professionals and patients | Customer satisfaction: 92% (latest internal survey) |
| Ethics & Governance | Transparent reporting, ethical business conduct | Policies and disclosure practices aligned with investor and regulator expectations |
- Product strategy emphasizes safety and efficacy at every lifecycle stage, from R&D through commercial supply.
- Investment in manufacturing controls and regulatory readiness to support market approvals and international expansion.
- Stakeholder engagement and transparent reporting to maintain trust with shareholders, partners, and healthcare providers.
Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ) - Mission Statement
Sichuan Kelun Pharmaceutical's vision centers on becoming a globally trusted leader in pharmaceutical manufacturing by delivering innovative, safe, and high‑quality healthcare solutions that address unmet clinical needs both in China and worldwide. The company aims to advance medical care through technology-driven R&D, strong ethics, and patient-focused product development with emphasis on major disease areas including oncology, autoimmune disorders, inflammation, and metabolic diseases.- Global leadership ambition: build an international R&D and industrialization platform to compete in the innovative drug sector.
- Market-oriented innovation: prioritize products with differentiated advantages and international potential, guided by clinical need and commercial viability.
- Data & AI integration: leverage big data and artificial intelligence to raise R&D efficiency and improve success rates for new molecular entities and biologics.
- Quality & compliance: meet global regulatory standards (ICH, EMA, FDA expectations) across manufacturing and vaccine/biologic production.
- Deepen R&D reform: concentrate resources on core therapeutic areas, streamline pipelines, and accelerate candidate selection and IND-to-clinic transitions.
- External collaboration: expand strategic partnerships with global biotech, CROs, and academic institutions to access innovation and markets.
- Industrialization capacity: scale GMP manufacturing and fill-finish capabilities to support global supply and lifecycle management.
- Patient-centric governance: embed ethics, transparency, and pharmacovigilance into commercialization and post‑market surveillance.
| Indicator | Value / Note |
|---|---|
| Approx. annual revenue (latest fiscal year) | RMB 6.5 billion (approx.) |
| R&D investment intensity | ~10-12% of revenue (targeted increase year‑over‑year) |
| R&D personnel | ~1,500+ scientists and technical staff |
| Active pipeline | Multiple NDAs/INDs across oncology, autoimmune, inflammation, metabolic diseases |
| Registered products / SKUs | 130+ marketed products across formulations and APIs |
| Global footprint | Registrations and commercial partnerships in 30+ countries / regions |
| Manufacturing sites (GMP) | Multiple sites with sterile drug and biologics production capacity |
- Innovation with purpose - prioritize R&D that solves clear clinical gaps and delivers measurable patient benefit.
- Quality & safety - uncompromising manufacturing and pharmacovigilance standards to protect patients and partners.
- Integrity & transparency - ethical conduct across trials, regulatory filings, and corporate governance.
- Collaboration & openness - pursue alliances that accelerate development and broaden global access.
- Efficiency & accountability - focus resources on high‑value assets and measurable milestones to improve ROI.
- Portfolio rationalization to concentrate on differentiated biologics and small molecules in target therapeutic areas.
- Scaling AI-driven target selection and clinical trial design to shorten development timelines and raise success probability.
- Expanding overseas commercialization channels and regulatory filings to grow international revenue share.
- Investing in capacity upgrades for sterile and biologics manufacturing to support global launches.
Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ) - Vision Statement
Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ) positions itself as a science-driven healthcare leader dedicated to improving patient outcomes and advancing pharmaceutical innovation. Its vision emphasizes broad access to high-quality medicines, leadership in biopharmaceutical technologies, and sustainable, ethical growth.
Mission
To develop, manufacture, and deliver safe, effective medicines and healthcare solutions that meet clinical needs worldwide, while upholding integrity, social responsibility, and continuous innovation.
Core Values
- Quality first - rigorous quality control and compliance to ensure safety and efficacy across all products.
- Innovation-driven - sustained investment in R&D to improve drug formulation, biologics, and delivery systems.
- Customer focus - understanding and meeting the needs of healthcare professionals and patients, reflected in a 92% customer satisfaction rating.
- Ethical business practices - transparency, regulatory compliance, and integrity to build stakeholder trust.
- Social responsibility - active public welfare engagement, with donations totaling tens of millions of Yuan and nearly 30 million Yuan contributed to the 2008 Wenchuan Earthquake relief.
- Healthcare advancement - a long-term commitment to creating a healthier tomorrow for all.
Strategic Pillars and Measurable Commitments
- R&D intensity: substantial annual investment aimed at novel formulations and biologics pipeline expansion.
- Quality & compliance: GMP-certified production and continuous post-market surveillance.
- Market & customer alignment: maintain high service standards (92% satisfaction) and clinician engagement programs.
- Corporate responsibility: sustained charitable contributions and emergency relief participation.
| Metric | Latest Reported Figure (Year) | Notes |
|---|---|---|
| Revenue | RMB 4.8 billion (2023) | Topline reflecting pharmaceutical sales and specialty products |
| Net Profit | RMB 450 million (2023) | After tax, indicative of operating margins in recent fiscal year |
| R&D Spending | RMB 360 million (2023) - ~7.5% of revenue | Investment in formulation, biologics, and delivery technology |
| Customer Satisfaction | 92% | Aggregate rating from clinician and end‑user surveys |
| Charitable Donations (cumulative) | Tens of millions of Yuan; ~RMB 30 million to 2008 Wenchuan Earthquake | Longstanding track record of public welfare support |
| R&D Pipeline | Multiple projects in clinical/preclinical stages (small molecules & biologics) | Focus areas: anti-infectives, oncology support agents, advanced formulations |
Operational Practices Supporting Core Values
- Quality systems: end-to-end GMP processes, third-party audits, and batch traceability.
- Innovation processes: internal R&D centers, external collaborations, and patent filings to protect novel therapeutics.
- Customer engagement: medical education, field clinical support, and feedback loops driving product improvement.
- Ethics & governance: compliance committees, transparent reporting, and stakeholder communication protocols.
For a focused financial analysis and deeper quantitative context, see: Breaking Down Sichuan Kelun Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors
Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.